Pure Extracts Receives Re-Order from Abba Medix Medical Platform for Vapes and Edibles
Pure Extracts Technologies Corp. (CSE: PULL, OTC: PRXTF) announced a re-order from Abba Medix Corp., a subsidiary of Canada House Wellness Group. This includes several SKUs of their Pure Pulls branded THC vape products and high potency CBD gummies. CEO Ben Nikolaevsky highlighted the significance of this re-order for Q4 revenue growth, benefiting from Abba's established medical customer base across Canada. The company's state-of-the-art facility in British Columbia is designed to meet EU GMP standards, aiming for international sales.
- Received a significant re-order from Abba Medix Corp, indicating strong demand.
- Projected revenue contributions starting in Q4 2021 and ramping up in 2022.
- Access to Abba's extensive military and medical customer base enhances market reach.
- None.
VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has received a re-order from Canada House Wellness Group’s (CSE: CHV) wholly owned subsidiary, Abba Medix Corp. (“Abba”) for vapes and gummies for sale to their established medical patient base.
Included in the re-order are several SKUs of our Pure Pulls branded line of full spectrum oil (FSO) THC vape products and our blister-packaged gummie products, including our high potency 50 mg CBD Pure Chews.
Pure Extracts’ CEO, Ben Nikolaevsky, commented, “We are pleased to be getting good sell-through in the medical cannabis space which will make a significant revenue contribution starting in Q4 and ramping-up in 2022. Abba’s extensive military and medical customer base along with their popular online portal allows us to quickly and efficiently get our outstanding line of full spectrum oil (FSO) CBD and THC vape products and high potency CBD chews, to their patients across Canada.”
ON BEHALF OF THE BOARD
“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director
About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.
Find out more at https://pureextractscorp.com/
Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com
This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.
This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from any agreements recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.
The CSE has neither approved nor disapproved the contents of this press release.
FAQ
What is the recent development for Pure Extracts Technologies Corp (PRXTF)?
How will the re-order from Abba Medix Corp impact Pure Extracts' revenue?
What products are included in Pure Extracts' re-order from Abba Medix Corp?
What is the significance of Abba Medix Corp's customer base for Pure Extracts?
